Thus, PD-1/PD-L1 inhibitors combined with SBRT instead of conventional radiotherapy might be more promising to fight against NSCLC, further achieving more favorable survival outcomes. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.